NASDAQ:ORMP

Oramed Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy ORMP

*Your capital is at risk

$4.07

-0.0500 (-1.21%)

At Close: Jul 31, 2026

Oramed Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -11.65. In total, the insiders bought 6.89M and sold 876.43K ORMP shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-11.65
● Buy	6.89M shares
● Sell	876.43K shares
94% Buy Activity Weak Negative Correlation
Sell Signal Low Confidence Jul 01, 2026 Analysis Breakdown: Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 31, 2025 Buy	Common Stock A-Award	Kidron Miriam Chief Scientific Officer	Officer	121 331 Value: $345.8K
Dec 31, 2025 Buy	Common Stock A-Award	Kidron Miriam Chief Scientific Officer	Officer	115 000 Value: $327.8K
Dec 31, 2025 Buy	Performance Stock Units A-Award	Kidron Nadav President And CEO	CEO / President	109 000 Value: $310.7K
Dec 31, 2025 Buy	Common Stock A-Award	Kidron Nadav President And CEO	CEO / President	232 640 Value: $663.0K
Dec 31, 2025 Buy	Common Stock A-Award	Kidron Nadav President And CEO	CEO / President	327 000 Value: $932.0K
Dec 31, 2025 Buy	Common Stock A-Award	Reznick Yehuda Director	Director	30 000 Value: $360
Dec 31, 2025 Buy	Common Stock A-Award	Reznick Yehuda Director	Director	6 250 Value: $17.8K
Dec 31, 2025 Buy	Common Stock A-Award	Shapiro Benjamin Director	Director	30 000 Value: $360
Dec 31, 2025 Buy	Common Stock A-Award	Mayer Arie Director	Director	4 900 Value: $14.0K
Dec 31, 2025 Buy	Common Stock A-Award	Mayer Arie Director	Director	30 000 Value: $360
Dec 31, 2025 Buy	Performance Stock Units A-Award	Gabay Avraham Chief Financial Officer	C-Suite Officer	19 000 Value: $54.2K
Dec 31, 2025 Buy	Common Stock A-Award	Gabay Avraham Chief Financial Officer	C-Suite Officer	81 216 Value: $231.5K
Dec 31, 2025 Buy	Common Stock A-Award	Aghion Daniel Director	Director	30 000 Value: $360
Dec 31, 2025 Buy	Common Stock A-Award	Gabay Avraham Chief Financial Officer	C-Suite Officer	115 000 Value: $327.8K
Dec 31, 2025 Buy	Common Stock A-Award	Aghion Daniel Director	Director	6 250 Value: $17.8K
Jun 05, 2025 Buy	Common Stock A-Award	Mayer Arie Director	Director	6 975 Value: $15.0K
Jun 05, 2025 Buy	Common Stock A-Award	Mayer Arie Director	Director	30 000 Value: $64.5K
Jun 05, 2025 Buy	Common Stock A-Award	Aghion Daniel Director	Director	8 371 Value: $18.0K
Jun 05, 2025 Buy	Common Stock A-Award	Aghion Daniel Director	Director	30 000 Value: $64.5K
Jun 05, 2025 Buy	Common Stock A-Award	Reznick Yehuda Director	Director	8 370 Value: $18.0K
Jun 05, 2025 Buy	Common Stock A-Award	Reznick Yehuda Director	Director	30 000 Value: $64.5K
Jun 05, 2025 Buy	Common Stock A-Award	Sank Leonard Director	Director	6 510 Value: $14.0K
Jun 05, 2025 Buy	Common Stock A-Award	Sank Leonard Director	Director	30 000 Value: $64.5K
Jun 05, 2025 Buy	Common Stock A-Award	Shapiro Benjamin Director	Director	4 650 Value: $10K
Jun 05, 2025 Buy	Common Stock A-Award	Shapiro Benjamin Director	Director	30 000 Value: $64.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ORAMED PHARMACEUTICALS INC.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptid...

Read Full Profile Here